Immune checkpoint inhibitors (ICI) targeting the PD-1/PD-L1 pathway have been approved for recurrent and metastatic HNSCC patients in the first- and second-line settings [15–17]. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.